Evidence map›Paper›PMID 33997266›Full record

ArticleAdvanced therapeutics2021

Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating

Christopher B Rodell, Paige Baldwin, Bianca Fernandez, Ralph Weissleder, Srinivas Sridhar, J Matthew Dubach

Open access · greenAbstract read
In one paragraph

Article in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Christopher B RodellCenter for Systems Biology, Massachusetts General Hospital, Boston, MA.
Paige BaldwinDepartment of Bioengineering, Northeastern University, Boston, MA.
Bianca FernandezCenter for Systems Biology, Massachusetts General Hospital, Boston, MA.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Hospital, Boston, MA.
Srinivas SridharDepartment of Bioengineering, Northeastern University, Boston, MA.
J Matthew DubachCenter for Systems Biology, Massachusetts General Hospital, Boston, MA.
Massachusetts General Hospital · USNortheastern University · USHarvard University · US

Funding

Training Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1M
Optimizing PARP inhibitor therapy through novel approaches to resolve the molecular mechanisms of responseR01CA241179 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DUBACH, JOHN · 2019 to 2023
$1.9M
The role of PARP inhibitor target engagement in breast cancerR00CA198857 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI DUBACH, JOHN · 2017 to 2019
$738k
NCI NIH HHS R00 CA198857NCI NIH HHS R01 CA241179NCI NIH HHS T32 CA079443
6 · The paper itself

Abstract

Nanoencapsulated drug delivery to solid tumors is a promising approach to overcome pharmacokinetic limitations of therapeutic drugs. However, encapsulation leads to complex drug biodistribution and delivery making analysis of delivery efficacy challenging. As proxies, nanocarrier accumulation or total tumor drug uptake in the tumor are used to evaluate delivery. Yet, these measurements fail to assess delivery of active, released drug to the target, and thus it commonly remains unknown if drug-target occupancy has been achieved. Here, we develop an approach to evaluate the delivery of encapsulated drug to the target, where residual drug target vacancy is measured using a fluorescent drug analog.

Indexed as

biodistributiondrug deliveryfractional occupancyin vivonanomedicine

Identifiers

PMID33997266
PMCPMC8114878
OpenAlexW3112054971

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.